Israel’s Endospan (see here previously) shared good early news from the trial on 22 patients of its Nexus Aortic Arch Stent Graft System. The trial is being extended to 110 patients. 120,000+ patients suffer thoracic aortic arch disease every year in the USA and Europe.

https://www.businesswire.com/news/home/20240130700861/en/Endospan-Releases-Early-TRIOMPHE-IDE-Study-Results-at-Society-of-Thoracic-Surgeons